Merck, Pfizer Diabetes Therapy Meets Late-Stage Study Goals
September 15 2016 - 10:03AM
Dow Jones News
By Tess Stynes
Merck & Co. Inc. (MRK) and Pfizer Inc. (PFE) said their
investigational diabetes treatment helped lower blood-glucose
levels in patients with hard-to-treat cases of type 2 diabetes,
meeting the main targets in a late-stage clinical study.
The phase 3 study data was presented at an industry conference
in Germany.
The treatment--called ertugliflozin--when used along with
Merck's Januvia and another traditional diabetes drug showed
significantly greater reductions in blood sugar levels than a
placebo.
"Type 2 diabetes is a progressive disease and these study
results help support the clinical profile of ertugliflozin as an
add-on therapy for patients who may require multiple treatment
combinations to help reach their blood sugar goals," said James
Rusnak, Pfizer chief development officer, cardiovascular and
metabolics.
The drug makers plan to file new drug applications with the U.S.
Food and Drug Administration by the end of the year and to seek
additional approvals outside the U.S. next year.
Ertugliflozin belongs to a class of therapies called SGLT2
inhibitors, which help lower blood sugar in people with type 2
diabetes by causing excretion of glucose in urine.
Write to Tess Stynes at tess.stynes@wsj.com
(END) Dow Jones Newswires
September 15, 2016 09:48 ET (13:48 GMT)
Copyright (c) 2016 Dow Jones & Company, Inc.
Merck (NYSE:MRK)
Historical Stock Chart
From Mar 2024 to Apr 2024
Merck (NYSE:MRK)
Historical Stock Chart
From Apr 2023 to Apr 2024